Eric Rubin

Nature Reviews Drug Discovery 16, 820 (2017). doi:10.1038/nrd.2017.228 Eric Rubin started as Vice President of clinical oncology at Merck & Co. in 2008. Since then, he has helped to turn the PD1-targeting pembrolizumab from an almost forgotten antibody into a blockbuster immunotherapy. He also secured a first approval for a tumour-agnostic cancer indication with pembrolizumab earlier this year, and is overseeing more than 300 combination trials to push this drug into more oncology settings. He spoke with Asher Mullard about the future of tumour-agnostic cancer approvals, the complexity of immunotherapy combination trials and recent efforts to modernize cancer trial eligibility criteria.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research